The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $611,129 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Terasaki Institute for Biomedical Innovation. This 4-year award, spanning from August 2024 to June 2028, aims to develop and validate a multi-organ-on-a-chip (MOC) platform comprised of a vascularized liver-on-a-chip and heart-on-a-chip model. The MOC platform will integrate a microfluidic electrochemical biosensor...
This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $235,500 to Rutgers, The State University of New Jersey to conduct research on identifying alternative receptors for SARS-CoV-2 in oral epithelial cells. The key objectives are to determine the repertoire of SARS-CoV-2 receptors and infection profiles in region-specific oral epithelial cells and tissues from...
This $131,988 Project Grant from the National Heart, Lung and Blood Institute, part of the Department of Health and Human Services, supports research targeting determinants of SARS-CoV-2 host interaction in airways. Funded through the Cardiovascular Diseases Research program, the grant aims to identify master regulator proteins that mechanistically regulate SARS-CoV-2 interactions in the airways. Using organotypic airway epithelial culture and systems biology tools at Columbia University, the...
This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...
This $1,000,000 Cooperative Agreement awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports research and development efforts by Akanocure Pharmaceuticals Inc. to optimize a novel, broad-spectrum antiviral and immunomodulatory agent for oral administration against coronaviruses. The project focuses on lead optimization, including the design, synthesis, and testing of analogs with improved drug-like properties for...
This Project Grant award of $437,477.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a "human lymph node-on-a-chip" microphysiological system. The goal is to create an in vitro model that accurately replicates the key functional compartments, cell types, and dynamic processes of the human lymph node environment to provide a more clinically relevant platform for...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel high-throughput screening (HTS) assay platform that can directly monitor drug-induced changes in RNA levels of dengue and influenza viruses. The $300,000 award to Lucerna Inc., a minority-owned small disadvantaged business, will fund the creation of this HTS-compatible cell-based reporter system to...
This $304,119 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of innovative in vitro 3D atherosclerosis models and high-throughput drug screening assays by Endomimetics LLC. The key objectives are to create an automated, precise approach for fabricating advanced 3D vascular sheet and atherosclerosis models, which will enable efficient, high-throughput testing of drug...
This federal Project Grant award of $867,563 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a pioneering class of nanobodies designed to provide comprehensive protection against all betacoronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. The research aims to strategically expand nanobody repertoires, identify synergistic nanobody pairs, and optimize critical...
This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...